Paper36034865
Engaging plasticity: Differentiation therapy in solid tumors.
Bar-Hai N and 1 other. Front Pharmacol, 2022. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Engaging plasticity: Differentiation therapy in solid tumors. Papers, record 36034865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36034865
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References169
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15717297 | Histone deacetylation in epigenetics: an attractive target for anticancer therapy. | Med Res Rev | 2005 | https://conductscience.org/library/papers/15717297 | PubMed |
| 2 | 22901808 | The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. | Cell | 2012 | https://conductscience.org/library/papers/22901808 | PubMed |
| 3 | 27832522 | Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells. | Mol Neurobiol | 2017 | https://conductscience.org/library/papers/27832522 | PubMed |
| 4 | 23014973 | Retinoic acid regulates commitment of undifferentiated mesenchymal stem cells into osteoblasts and adipocytes. | J Bone Miner Metab | 2013 | https://conductscience.org/library/papers/23014973 | PubMed |
| 5 | 11282573 | Histone acetylation and the cell-cycle in cancer. | Front Biosci | 2001 | https://conductscience.org/library/papers/11282573 | PubMed |
| 6 | 19169796 | EMT, the cytoskeleton, and cancer cell invasion. | Cancer Metastasis Rev | 2009 | https://conductscience.org/library/papers/19169796 | PubMed |
| 7 | 23201163 | Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. | Cancer Cell | 2012 | https://conductscience.org/library/papers/23201163 | PubMed |
| 8 | 17612559 | The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. | J Surg Res | 2007 | https://conductscience.org/library/papers/17612559 | PubMed |
| 9 | 21612856 | Retinoic acid-induced Smad3 expression is required for the induction of osteoblastogenesis of mesenchymal stem cells. | Differentiation | 2011 | https://conductscience.org/library/papers/21612856 | PubMed |
| 10 | 23972859 | Coupled reversible and irreversible bistable switches underlying TGFβ-induced epithelial to mesenchymal transition. | Biophys J | 2013 | https://conductscience.org/library/papers/23972859 | PubMed |
| 11 | 14612500 | Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. | Cancer Res | 2003 | https://conductscience.org/library/papers/14612500 | PubMed |
| 12 | 22576165 | To differentiate or not--routes towards metastasis. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22576165 | PubMed |
| 13 | 32083171 | Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. | Sci Adv | 2020 | https://conductscience.org/library/papers/32083171 | PubMed |
| 14 | 33675037 | The EMT transcription factor ZEB1 blocks osteoblastic differentiation in bone development and osteosarcoma. | J Pathol | 2021 | https://conductscience.org/library/papers/33675037 | PubMed |
| 15 | 9734398 | Differentiation and reversal of malignant changes in colon cancer through PPARgamma. | Nat Med | 1998 | https://conductscience.org/library/papers/9734398 | PubMed |
| 16 | 34847378 | Distinct contributions of partial and full EMT to breast cancer malignancy. | Dev Cell | 2021 | https://conductscience.org/library/papers/34847378 | PubMed |
| 17 | 11731433 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. | Cancer Res | 2001 | https://conductscience.org/library/papers/11731433 | PubMed |
| 18 | 29079737 | miR-1199-5p and Zeb1 function in a double-negative feedback loop potentially coordinating EMT and tumour metastasis. | Nat Commun | 2017 | https://conductscience.org/library/papers/29079737 | PubMed |
| 19 | 17417771 | Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17417771 | PubMed |
| 20 | 26077423 | Small molecule inhibitors of EZH2: the emerging translational landscape. | Epigenomics | 2015 | https://conductscience.org/library/papers/26077423 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42491051 | Drosophila neural stem cell division and human tumorigenesis: fail to divide (asymmetrically) and tumors…will conquer? | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42491051 | PubMed |
| 42236828 | When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42236828 | PubMed |
| 41372554 | Pleiotropic effects of all-trans retinoic acid in attenuating the hallmarks of colorectal cancer- challenges and scope of differentiation therapy. | Cancer Gene Ther | 2026 | https://conductscience.org/library/papers/41372554 | PubMed |
| 41318947 | Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro. | Adv Biol (Weinh) | 2026 | https://conductscience.org/library/papers/41318947 | PubMed |
| 41225636 | Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41225636 | PubMed |
| 40426233 | Ephrin-A5 or EphA7 stimulation is anti-proliferative for human rhabdomyosarcoma in vitro. | Skelet Muscle | 2025 | https://conductscience.org/library/papers/40426233 | PubMed |
| 40413503 | Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40413503 | PubMed |
| 40259075 | Tumor heterogeneity in retinoblastoma: a literature review. | Cancer Metastasis Rev | 2025 | https://conductscience.org/library/papers/40259075 | PubMed |
| 40076613 | Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076613 | PubMed |
| 39710702 | Ferroptosis, a therapeutic target for cardiovascular diseases, neurodegenerative diseases and cancer. | J Transl Med | 2024 | https://conductscience.org/library/papers/39710702 | PubMed |
| 39363281 | Comprehensive transcriptomic analysis identifies three distinct subtypes of pituitary adenomas: insights into tumor behavior, prognosis, and stem cell characteristics. | J Transl Med | 2024 | https://conductscience.org/library/papers/39363281 | PubMed |
| 39273076 | Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. | Cells | 2024 | https://conductscience.org/library/papers/39273076 | PubMed |
| 38482207 | Editorial: Integrating transcriptional modulation in systemic tumor therapy. | Front Oncol | 2024 | https://conductscience.org/library/papers/38482207 | PubMed |
| 38457060 | Initiation of Cancer: The Journey From Mutations in Somatic Cells to Epigenetic Changes in Tissue-resident VSELs. | Stem Cell Rev Rep | 2024 | https://conductscience.org/library/papers/38457060 | PubMed |
| 38273846 | Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. | Front Oncol | 2023 | https://conductscience.org/library/papers/38273846 | PubMed |
| 38201607 | Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201607 | PubMed |
| 38158755 | Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38158755 | PubMed |
| 37858275 | Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells. | Clin Epigenetics | 2023 | https://conductscience.org/library/papers/37858275 | PubMed |
| 37628798 | A Novel Transgenic Mouse Model Implicates Sirt2 as a Promoter of Hepatocellular Carcinoma. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37628798 | PubMed |
| 37625115 | Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/37625115 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36034865
GET https://conductscience.org/api/papers/v1/36034865/references?page=2